玻璃体切除术前抗血管内皮生长因子药物预处理治疗复杂性增殖性糖尿病视网膜病变:随机对照试验的Meta分析
该Meta分析纳入14项随机对照试验共613例患者,评估玻璃体切除术前抗血管内皮生长因子(anti-VEGF)预处理对复杂性增殖性糖尿病视网膜病变(PDR)的疗效。结果显示预处理组术中出血更少、手术时间更短、医源性视网膜裂孔更少,术后最佳矫正视力更好、早期复发性玻璃体出血更少且吸收更快(均P<0.05)。但晚期复发性玻璃体出血、复发性视网膜脱离及相关二次手术的发生率未降低(P>0.05)。作者认为未来需更大样本的更好设计研究进一步评估不同anti-VEGF药物的疗效。
要点
- 抗VEGF预处理可减少术中出血、缩短手术时间、减少医源性视网膜裂孔(P<0.05)。
- 预处理组术后最佳矫正视力更好、早期复发性玻璃体出血更少且吸收更快(P<0.05)。
- 晚期复发性玻璃体出血、复发性视网膜脱离及相关二次手术发生率未降低(P>0.05)。
核心结论
- 复杂性PDR患者玻璃体切除术前anti-VEGF预处理可能有助于手术更易进行、视力康复更好、降低早期复发性玻璃体出血率并加速其吸收。
- 作者指出未来需要更大样本的更好设计研究进一步评估不同anti-VEGF药物的疗效并得出更确切结论。
研究设计与样本
- Meta分析,检索PubMed、Embase和Cochrane对照试验中心注册库至2017年6月,遵循PRISMA指南,使用StataSE V.12.0软件分析。
- 纳入14项随机对照试验共613例患者,anti-VEGF预处理组289例,对照组324例。
主要发现
- 预处理组术中出血更少、内电凝更少、手术时间更短、医源性视网膜裂孔更少、硅油使用和视网膜切开频率更低(P<0.05)。
- 预处理组术后最佳矫正视力更好、早期复发性玻璃体出血更少且吸收更快(P<0.05)。
- 晚期复发性玻璃体出血、复发性视网膜脱离或相关二次手术的发生率未降低(P>0.05)。
关键数值与推荐
- 采用加权均数差、相对危险度及其95%CI评估关联强度。
- 14项随机对照试验,anti-VEGF预处理组289例 vs 对照组324例。
临床怎么用
- 原文结论认为anti-VEGF预处理可能使复杂性PDR玻璃体切除术更易进行并改善视力康复。
局限性
- 作者指出未来需要更大样本的更好设计研究进一步评估不同anti-VEGF药物的疗效并得出更确切结论。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND/AIMS: To evaluate the efficacy of antivascular endothelial growth factor (anti-VEGF) agents pretreatment before vitrectomy for patients with complicated proliferative diabetic retinopathy (PDR). METHODS: The PubMed, Embase and the Cochrane Central Register of Controlled Trials were searched up to June 2017 to identify related studies. The Peferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines were followed. The StataSE V.12.0 software was used to analyse the relevant data. The weighted mean difference, relative risk and their 95% CIs were used to assess the strength of the association. RESULTS: 14 randomised controlled trials involving 613 patients were assessed, the anti-VEGF pretreatment group included 289 patients and the control group included 324 patients. Our analysis indicated that anti-VEGF pretreatment before vitrectomy for complicated PDR could facilitate much easier surgery regarding less intraoperative bleeding, less endodiathermy, shorter duration of surgery, less iatrogenic retinal breaks, less frequency of using silicone oil and relaxing retinotomy (P<0.05). Additionally, anti-VEGF pretreatment could also achieve better postoperative best-corrected visual acuity, less early recurrent vitreous haemorrhage (VH) and quicker absorption of recurrent VH (P<0.05). However, the incidence of late recurrent VH, recurrent retinal detachment or related secondary surgery could not be reduced (P>0.05). CONCLUSION: The pretreatment of anti-VEGF agents before vitrectomy for patients with complicated PDR might facilitate much easier surgery and better visual rehabilitation, reduce the rate of early recurrent VH and accelerate its absorption. Moreover, future better-designed studies with larger sample sizes are required to further evaluate the efficacy of different anti-VEGF agents and reach a firmer conclusion.
引用
- Zhao XY, Xia S, Chen YX, et al. Antivascular endothelial growth factor agents pretreatment before vitrectomy for complicated proliferative diabetic retinopathy: a meta-analysis of randomised controlled trials. Br J Ophthalmol. 2017. PMID: 29246890. doi:10.1136/bjophthalmol-2017-311344
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。